Evidence map›Paper›PMID 37098956›Full record

ArticleJournal of virology2023

Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.

Mallika Sastry, Anita Changela, Jason Gorman, Kai Xu, Gwo-Yu Chuang, Chen-Hsiang Shen, Cheng Cheng, Hui Geng, Sijy O'Dell, Li Ou and 28 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Status of HIV vaccine development: progress and promise.Journal of the International AIDS Society · 2025
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 3 institutions in 1 country.

Mallika Sastry *Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Anita Changela *Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Jason GormanVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Kai XuVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Gwo-Yu ChuangVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Chen-Hsiang ShenVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Cheng ChengVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Hui GengVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Sijy O'DellVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Li OuVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Reda RawiVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Mateo ReveizVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Guillaume B E Stewart-JonesVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Shuishu WangVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Baoshan ZhangVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Tongqing ZhouVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-3935-4637
Andrea BijuVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Michael ChambersVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Xuejun ChenVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Angela R CorriganVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Bob C LinVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Mark K LouderVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Krisha McKeeVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Alexandra F NazzariVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Adam S OliaVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Danealle K ParchmentVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-4724-1093
Edward K SarfoVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Tyler StephensElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Jonathan StuckeyVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Raffaello VerardiVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Yiran WangVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Cheng-Yan ZhengVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Yuling ChenGenscript USA, Piscataway, New Jersey, USA.
Nicole A Doria-RoseVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Adrian B McDermottVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
John R MascolaVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Peter D KwongVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-3560-232X
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USAllscripts (United States) · US

Funding

Vaccine Immunology ProgramZIAAI005143 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2019 to 2025
$51.8M
Neutralization Mechanisms Of Anti-HIV-1 Monoclonal AntibodiesZIAAI005022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$24.6M
HIV/AIDS Vaccine and Antibody DevelopmentZICAI005002 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHENG, CHENG · 2019 to 2025
$17.6M
TRD #3: An automated and streamlined pipeline for in-situ molecular microscopyP41GM103310 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2012 to 2021
$14.7M
Design of Antigenically-Specific Probes for Sera Analysis and MAb IsolationZICAI005111 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2010 to 2025
$4.3M
Computational Tools for Structural AnalysisZICAI005112 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2010 to 2025
$4.1M
Structure, function, and antigenicity of emerging henipavirus surface glycoproteinsU01AI173348 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Kai Xu · 2023 to 2026
$2.4M
Neutralization Mechanisms Of HIV-1 Monoclonal AntibodiesZ01AI005022 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI KWONG, PETER D · 2002 to 2008
$733k
Targeting glycoprotein (G) domain-III for pan-lyssavirus nanobody therapeuticsUH2AI171611 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI XU, KAI · 2023 to 2024
$423k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 AI005022Intramural NIH HHS ZIA AI005022NCI NIH HHS HHSN2612008000016CNCI NIH HHS HHSN261200800001ENIAID NIH HHS U01 AI173348NIAID NIH HHS UH2 AI171611NIGMS NIH HHS P41 GM103310
6 · The paper itself

Abstract

While neutralizing antibodies that target the HIV-1 fusion peptide have been elicited in mice by vaccination, antibodies reported thus far have been from only a single antibody class that could neutralize ~30% of HIV-1 strains. To explore the ability of the murine immune system to generate cross-clade neutralizing antibodies and to investigate how higher breadth and potency might be achieved, we tested 17 prime-boost regimens that utilized diverse fusion peptide-carrier conjugates and HIV-1 envelope trimers with different fusion peptides. We observed priming in mice with fusion peptide-carrier conjugates of variable peptide length to elicit higher neutralizing responses, a result we confirmed in guinea pigs. From vaccinated mice, we isolated 21 antibodies, belonging to 4 distinct classes of fusion peptide-directed antibodies capable of cross-clade neutralization. Top antibodies from each class collectively neutralized over 50% of a 208-strain panel. Structural analyses - both X-ray and cryo-EM - revealed each antibody class to recognize a distinct conformation of fusion peptide and to have a binding pocket capable of accommodating diverse fusion peptides. Murine vaccinations can thus elicit diverse neutralizing antibodies, and altering peptide length during prime can improve the elicitation of cross-clade responses targeting the fusion peptide site of HIV-1 vulnerability.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsHIV SeropositivityAnimalsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusGuinea PigsHIV AntibodiesImmunoglobulin IsotypesMicePeptidesVaccinationAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesImmunoglobulin IsotypesPeptidescryo-EMfusion peptideHIV-1neutralizing antibodyX-ray crystallography

Identifiers

PMID37098956
PMCPMC10234334
OpenAlexW4367048078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.